KAZIA THERAPEUTICS-SPON ADR (KZIA)

US48669G1058 - ADR

0.3098  0 (-1.24%)

After market: 0.2804 -0.03 (-9.49%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (3/28/2024, 8:21:05 PM)

After market: 0.2804 -0.03 (-9.49%)

0.3098

0 (-1.24%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap8.17M
Shares
PEN/A
Fwd PE42.41
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KZIA Daily chart

Company Profile

Kazia Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Sydney, New South Wales. Kazia Therapeutics Limited is an oncology focused drug development company. The firm is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.

Company Info

KAZIA THERAPEUTICS-SPON ADR

Three International Towers Level 24,, 300 Barangaroo Avenue

Sydney NEW SOUTH WALES 2000

P: 1161298780088

CEO: James Garner

Employees: 0

Website: https://www.kaziatherapeutics.com/

KZIA News

News Image8 days ago - Kazia Therapeutics LimitedKazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an...

News Image9 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning!

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

News Imagea month ago - Seeking AlphaKazia concludes Phase 1 study for paxalisib early due to promising data (NASDAQ:KZIA)

Kazia (KZIA) said it has concluded a Phase 1 trial for its drug paxalisib in the treatment of a certain type of brain metastases early due to encouraging data. Read more here.

News Imagea month ago - Kazia Therapeutics LimitedKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on...

News Image2 months ago - Kazia Therapeutics LimitedKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma...

KZIA Twits

Here you can normally see the latest stock twits on KZIA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example